加拿大患者群体的商业资助与其对药品资助看法之间的关联：一项观察性研究。
Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study.
机构信息
School of Health Policy and Management, York University, Toronto, ON, Canada.
Emergency Department, University Health Network, Toronto, ON, Canada.
出版信息
PLoS One. 2019 Feb 15;14(2):e0212399. doi: 10.1371/journal.pone.0212399. eCollection 2019.
BACKGROUND
Patient groups represent the interest of their members when it comes to drug funding. Many patient groups receive grants from pharmaceutical companies that make products being considered for funding. This research examines whether there is an association between the positions that Canadian groups take about the products and conflicts of interest with the companies.
METHODS
The Common Drug Review (CDR) and panCanadian Oncology Drug Review (pCODR) make recommendations to Canadian provincial and federal drug plans about funding particular drug-indications. Both utilize input from patient groups in making their recommendations. Patient group submissions are available from both organizations and these submissions contain statements about conflicts of interest. Views of the patient groups, with and without a conflict with the company making the drug under consideration and without any conflicts at all, were assessed and then compared with the recommendations from CDR and pCODR.
RESULTS
There was a total of 222 reports for drug-indications. There were 372 submissions from 93 different patient groups. Groups declared a total of 1896 conflicts with drug companies in 324 (87.1%) individual submissions. There were 268 submissions where groups declared a conflict with the company making the product or said they had no conflict. Irrespective of whether there was a conflict, the views of patient groups about the drug-indications under consideration were the same. There was no statistically significant difference between views of patient groups and the recommendations from CDR and/or pCODR.
CONCLUSIONS
The large majority of patient groups making submissions about funding of particular drug-indications had conflicts with the companies making the products and their views about the products were almost always positive. This association between funding and views needs to be further investigated to determine if a true cause and effect exists.
背景
患者群体在药物资金方面代表其成员的利益。许多患者群体从制药公司获得资助，而这些公司生产的产品正在考虑获得资金。本研究旨在调查加拿大各团体对产品的立场与公司利益冲突之间是否存在关联。
方法
加拿大药品评审局（CDR）和泛加拿大肿瘤药物评审局（pCODR）就特定药物适应症的资金问题向加拿大省级和联邦药品计划提出建议。这两个机构在做出建议时都利用了患者群体的意见。这两个机构都提供了患者群体的提交材料，其中包含有关利益冲突的声明。评估了有、无与正在审议药物的公司存在利益冲突以及无任何冲突的患者群体的意见，并将其与 CDR 和 pCODR 的建议进行了比较。
结果
共有 222 项药物适应症报告。93 个不同的患者群体共提交了 372 份材料。324 份（87.1%）个别提交材料中，各团体共声明与制药公司存在 1896 项冲突。有 268 份提交材料显示团体与生产该产品的公司存在冲突或表示无冲突。无论是否存在冲突，患者群体对正在审议的药物适应症的看法都是一致的。患者群体的观点与 CDR 和/或 pCODR 的建议之间没有统计学上的显著差异。
结论
大多数提交有关特定药物适应症资金的患者群体与生产这些产品的公司存在利益冲突，并且他们对这些产品的看法几乎总是积极的。需要进一步调查资金与观点之间的这种关联，以确定是否存在真正的因果关系。
Zotero 插件